QualityStocks would like to highlight Chembio Diagnostics (
NASDAQ: CEMI). The company develops, manufactures, licenses, and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies.
In the company’s news,
Chembio Diagnostics announced that European regulators have granted CE Mark approval for the company’s SURE CHECK HIV 1/2 Assay. Now cleared for commercialization within the European Union for rapid, point-of-care detection of HIV, the SURE CHECK HIV 1/2 Assay is also FDA approved and is being distributed in the United States by Alere NA as Clearview COMPLETE HIV 1/2.
Currently, Chembio is working with commercialization partners in Europe and anticipates sales of the SURE CHECK HIV 1/2 Assay in the E.U. by Q1 of 2014. In France alone, the administration of 5.2 million HIV tests (serological) was reported in 2012, and there were more than 28,000 new HIV diagnoses in the EU and European Economic Area (EEA) in 2011, according to the European Centre for Disease Prevention and Control and the World Health Organization Regional Office for Europe. As concluded in the 2011 European HIV/AIDS surveillance report published by these groups: “HIV infection is of major public health importance in Europe, with evidence of continuing transmission in specific populations with no clear signs of overall decrease.”
Chembio is focused on developing superior diagnostics to facilitate rapid detection and early treatment of HIV and other infectious diseases. This recently granted CE Mark gives the company an opportunity to bring these key diagnostics to the European market, which is an area that continues to see an increase in HIV among certain significant populations. Chembio will continue working with regulators in Europe to obtain CE Marks for several other diagnostic products this year, as well, including the HIV 1/2 STAT-PAK test, the DPP HIV 1/2 Oral Fluid test and the DPP Syphilis test.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.com
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
